Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Rossignol

Showing results (431-440 of 461) with videos related to

Pageof 47
Sort By:
The American Journal of Medicine|May 26, 2025
Higher Risk of Kidney Failure Associated With Angiotensin Receptor Blockers vs ACE Inhibitors in Patients With Heart FailureHans J Moore, Wen-Chih Wu, Paul A Heidenreich, et al.
Heart (British Cardiac Society)|May 10, 2024
Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trialYu-Ling Yu, Justyna Siwy, De-Wei An, et al.
European Journal of Heart Failure|September 8, 2022
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of CardiologyAntoni Bayes-Genis, Alberto Aimo, Pardeep Jhund, et al.
European Heart Journal Open|August 3, 2022
Fatty acid desaturase genetic variations and dietary omega-3 fatty acid intake associate with arterial stiffnessMagnus Bäck, Constance Xhaard, Raphael Rouget, et al.
Journal of the American College of Cardiology|September 25, 2024
Patiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients With Heart Failure and HyperkalemiaBertram Pitt, Stefan D Anker, Lars H Lund, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|February 18, 2020
Enhanced clinical phenotyping by mechanistic bioprofiling in heart failure with preserved ejection fraction: insights from the MEDIA-DHF study (The Metabolic Road to Diastolic Heart Failure)Susan Stienen, João Pedro Ferreira, Masatake Kobayashi, et al.
European Heart Journal|September 4, 2012
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practiceFaiez Zannad, Wendy Gattis Stough, Patrick Rossignol, et al.
Biology of Sex Differences|August 25, 2020
Sex differences in circulating proteins in heart failure with preserved ejection fractionSusan Stienen, João Pedro Ferreira, Masatake Kobayashi, et al.
Lancet (London, England)|August 16, 2025
Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysisPatrick Rossignol, Faiez Zannad, Ziad Massy, et al.
Circulation. Heart Failure|May 21, 2019
Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart FailureJoão Pedro Ferreira, Job Verdonschot, Timothy Collier, et al.
Pageof 47

Showing results (431-440 of 461) with videos related to

Sort By:
Pageof 47
The American Journal of Medicine|May 26, 2025
Higher Risk of Kidney Failure Associated With Angiotensin Receptor Blockers vs ACE Inhibitors in Patients With Heart FailureHans J Moore, Wen-Chih Wu, Paul A Heidenreich, et al.
Heart (British Cardiac Society)|May 10, 2024
Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trialYu-Ling Yu, Justyna Siwy, De-Wei An, et al.
European Journal of Heart Failure|September 8, 2022
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of CardiologyAntoni Bayes-Genis, Alberto Aimo, Pardeep Jhund, et al.
European Heart Journal Open|August 3, 2022
Fatty acid desaturase genetic variations and dietary omega-3 fatty acid intake associate with arterial stiffnessMagnus Bäck, Constance Xhaard, Raphael Rouget, et al.
Journal of the American College of Cardiology|September 25, 2024
Patiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients With Heart Failure and HyperkalemiaBertram Pitt, Stefan D Anker, Lars H Lund, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|February 18, 2020
Enhanced clinical phenotyping by mechanistic bioprofiling in heart failure with preserved ejection fraction: insights from the MEDIA-DHF study (The Metabolic Road to Diastolic Heart Failure)Susan Stienen, João Pedro Ferreira, Masatake Kobayashi, et al.
European Heart Journal|September 4, 2012
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practiceFaiez Zannad, Wendy Gattis Stough, Patrick Rossignol, et al.
Biology of Sex Differences|August 25, 2020
Sex differences in circulating proteins in heart failure with preserved ejection fractionSusan Stienen, João Pedro Ferreira, Masatake Kobayashi, et al.
Lancet (London, England)|August 16, 2025
Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysisPatrick Rossignol, Faiez Zannad, Ziad Massy, et al.
Circulation. Heart Failure|May 21, 2019
Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart FailureJoão Pedro Ferreira, Job Verdonschot, Timothy Collier, et al.
Pageof 47